Ras-dependent oncolysis with an adenovirus VAI mutant

Cancer Research

Volumn 63, Issue 17, 2003, Pages 5544-5550

  Cascalló, Manel ^a   Capellà, Gabriel ^a   Mazo, Adela ^b   Alemany, Ramon ^a  

^a CATALAN INSTITUTE OF ONCOLOGY   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOVIRUS VECTOR; GENE PRODUCT; PROTEIN KINASE; UNCLASSIFIED DRUG; VAI RNA; VIRUS PROTEIN; VIRUS RNA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GENETICS; CONTROLLED STUDY; EMBRYO; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; ONCOGENE; ONCOGENE RAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; PROTEIN SYNTHESIS; TUMOR CELL DESTRUCTION; TUMOR SUPPRESSOR GENE; VIRAL GENE THERAPY; VIRUS MUTANT; VIRUS REPLICATION;

ADENOVIRUSES, HUMAN; CYTOPATHOGENIC EFFECT, VIRAL; EIF-2 KINASE; ENZYME ACTIVATION; HUMANS; PANCREATIC NEOPLASMS; RAS PROTEINS; RNA, VIRAL; TUMOR CELLS, CULTURED; VIRUS REPLICATION;

EID: 0141592775     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Katze, M. G., He, Y., and Gale, M., Jr. Viruses and interferon: a fight for supremacy. Nat. Rev. Immunol., 2: 675-687, 2002.
2. Meurs, E., Chong, K., Galabru, J., Thomas, N. S., Kerr, I. M., Williams, B. R., and Hovanessian, A. G. Molecular cloning and characterization of the human double-stranded RNA-activated protein kinase induced by interferon. Cell, 62: 379-390, 1990.
3. Williams, B. R. PKR; a sentinel kinase for cellular stress. Oncogene, 18: 6112-6120, 1999.
4. Grander, D., and Einhorn, S. Interferon and malignant disease-how does it work and why doesn't it always? Acta Oncol., 37: 331-338, 1998.
5. Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Sterman, D., Marshall, J. L., Goldberg, S., Gross, P., O'Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K., and Lorence, R. M. Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. J. Clin. Oncol., 20: 2251-2266, 2002.
6. Stojdl, D. F., Lichty, B., Knowles, S., Marius, R., Atkins, H., Sonenberg, N., and Bell, J. C. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat. Med., 6: 821-825, 2000.
7. Mundschau, L. J., and Faller, D. V. Oncogenic ras induces an inhibitor of double-stranded RNA-dependent eukaryotic initiation factor 2 alpha-kinase activation. J. Biol. Chem., 267: 23092-23098, 1992.
8. Strong, J. E., Coffey, M. C., Tang, D., Sabinin, P., and Lee, P. W. The molecular basis of viral oncolysis: usurpation of the Ras signaling pathway by reovirus. EMBO J., 17: 3351-3362, 1998.
9. Bergmann, M., Romirer, I., Sachet, M., Fleischhacker, R., Garcia-Sastre, A., Palese, P., Wolff, K., Pchamberger, H., Jakesz, R., and Muster, T. A genetically engineered influenza A virus with ras-dependent oncolytic properties. Cancer Res., 61: 8188-8193, 2001.
10. Farassati, F., Yang, A. D., and Lee, P. W. Oncogenes in Ras signaling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nat. Cell Biol., 3: 745-750, 2001.
11. Alemany, R., Balague, C., and Curiel, D. T. Replicative adenoviruses for cancer therapy. Nat. Biotechnol., 18: 723-727, 2000.
12. Bischoff, J. R., Kim, D. H., Williams, A., Heise, C., Horn, S., Muna, M., Ng, L., Nye, J. A., Sampson-Johannes, A., Fattaey, A., and McCormick, F. An adenovirus mutant that replicates selectively in p53-deficient human tumor cells. Science (Wash. DC), 274: 373-376, 1996.
13. Fucyo, J., Gomez-Manzano, C., Alemany, R., Lee, P. S., McDonnell, T. J., Mitlianga, P., Shi, Y. X., Levin, V. A., Yung, W. K., and Kyritsis, A. P. A mutant oncolytic adenovirus targeting the Rb pathway produces anti-glioma effect in vivo. Oncogene, 19: 2-12, 2000.
14. Heise, C., Hermiston, T., Johnson, L., Brooks, G., Sampson-Johannes, A., Williams, A., Hawkins, L., and Kirn, D. An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy. Nat. Med., 6: 1134-1139, 2000.
15. Katze, M. G., DeCorato, D., Safer, B., Galabru, J., and Hovanessian, A. G. Adenovirus VAI RNA complexes with the 68 000 Mr protein kinase to regulate its autophosphorylation and activity. EMBO J., 6: 689-697, 1987.
16. Villanueva, A., Garcia, C., Paules, A. B., Vicente, M., Megias, M., Reyes, G., de Villalonga, P., Agell, N., Lluis, F., Bachs, O., and Capella, G. Disruption of the antiproliferative TGF-beta signaling pathways in human pancreatic cancer cells. Oncogene, 17: 1969-1978, 1998.
17. Gomez-Lechon, M. J., Lopez, P., Donato, T., Montoya, A., Larrauri, A., Gimenez, P., Trullenque, R., Fabra, R., and Castell, J. V. Culture of human hepalocytes from small surgical liver biopsies. Biochemical characterization and comparison with in vivo. In Vitro Cell. Dev. Biol., 26: 67-74, 1990.
18. Thimmappaya, B., Weinberger, C., Schneider, R. J., and Shenk, T. Adenovirus VAI RNA is required for efficient translation of viral mRNAs at late times after infection. Cell, 31: 543-551 1982.
19. Hu, Y., and Conway, T. W. 2-Aminopurine inhibits the double-stranded RNA-dependent protein kinase both in vitro and in vivo. J. Interferon Res., 13: 323-328, 1993.
20. He, J., Olson, J. J., Ekstrand, A. J., Serbanescu, A., Yang, J., Offermann, M. K., and James, C. D. Transfection of IFNalpha in human glioblastoma cells and tumorigenicity in association with induction of PKR and OAS gene expression. J. Neurosurg., 85: 1085-1090, 1996.
21. Whyte, D. B., Kirschmeier, P., Hockenberry, T. N., Nunez-Oliva, I., James, L., Catino, J. J., Bishop, W. R., and Pai, J. K. K- and N-Ras are geranylgeranylated in cells treated with farnesyl protein transferase inhibitors. J. Biol. Chem., 272: 14459-14464, 1997.
22. Cascallo, M., Mercade, E., Capella, G., Lluis, F., Fillat, C., Gomez-Foix, A. M., and Mazo, A. Genetic background determines the response to adenovirus-mediated wild-type p53 expression in pancreatic tumor cells. Cancer Gene Ther., 6: 428-436, 1999.
23. Cascallo, M., Calbo, J., Gelpi, J. L., and Mazo, A. Modulation of drug cytotoxicity by reintroduction of wild-type p53 gene (Ad5CMV-p53) in human pancreatic cancer. Cancer Gene Ther., 7: 545-556, 2000.
24. Pearson, A. S., Koch, P. E., Atkinson, N., Xiong, M., Finberg, R. W., Roth, J. A., and Fang, B. Factors limiting adenovirus-mediated gene transfer into human lung and pancreatic cancer cell lines. Clin. Cancer Res., 5: 4208-4213, 1999.
25. Wesseling, J. G., Bosma, P. J., Krasnykh, V., Kashentseva, E. A., Blackwell, J. L., Reynolds, P. N., Li, H., Parameshwar, M., Vickers, S. M., Jaffee, E. M., Huibregtse, K., Curiel, D. T., and Dmitriev, I. Improved gene transfer efficiency to primary and established human pancreatic carcinoma target cells via epidermal growth factor receptor and integrin-targeted adenoviral vectors. Gene Ther., 8: 969-976, 2001
26. Bhat, R., and Thimmappaya, B. Adenovirus mutants with DNA sequence perturbations in the intragenic promoter of VAI RNA gene allow the enhanced transcription of VAII RNA gene in HeLa cells. Nucleic Acid Res., 12: 7377-7388, 1984.
27. Kitajewski, J., Schneider, R. J., Safer, B., and Shenk, T. An adenovirus mutant unable to express VAI RNA displays different growth responses and sensitivity to interferon in various host cell lines. Mol. Cell. Biol., 6: 4493-4498, 1986.
28. Mercade, E., Cascallo, M., Carrio, M., Calbo, J., Gomez-Trevino, A., Fillat, C., Gomez-Foix, A. M., and Mazo, A. Treatment based on a combination of the CYP2B1/cyclophosphamide system and p53 delivery enhances tumour regression in human pancreatic cancer. Ann. Oncol., 12: 379-388, 2001.
29. Mulvihill, S., Warren, R., Venook, A., Adler, A., Randlev, B., Heise, C., and Kim, D. Safety and feasibility of injection with an E1B-55 kDa gene-deleted, replication-selective adenovirus (ONYX-015) into primary carcinomas of the pancreas: a phase I trial. Gene Ther., 8: 308-315, 2001.
30. Suzuki, K., Fueyo, J., Krasnykh, V., Reynolds, P. N., Curiel, D. T., and Alemany, R. A conditionally replicative adenovirus with enhanced infectivity shows improved oncolytic potency. Clin. Cancer Res., 7: 120-126, 2001.
31. Suzuki, K., Alemany, R., and Curiel, D. T. The presence of the adenovirus E3 gene improves the oncolytic potency of conditionally replicative adenoviruses. Clin. Cancer Res., 8: 3348-3359, 2002.
32. Lamfers, M. L., Grill, J, Dirven, C. M., Van Beusechem, V. W., Geoerger, B., Van Den Berg, J., Alemany, R., Fueyo, J., Curiel, D. T., Vassal, G., Pinedo, H. M., Vandertop, W. P., and Gerritsen, W. R. Potential of the conditionally replicative adenovirus Ad5-Delta24RGD in the treatment of malignant gliomas and its enhanced effect with radiotherapy. Cancer Res., 62: 5736-5742, 2002.
33. Evans, D. B., Abbruzzese, J. L., and Rich, T. R. (eds.). Cancer of the Pancreas. Ed. 5, pp. 1054-1087. Philadelphia: Lippincot-Raven, 1997.
34. Macaluso, M., Russo, G., Cinti, C., Bazan, V., Gebbia, N., and Russo, A. Ras family genes: an interesting link between cell cycle and cancer. J. Cell. Physiol., 192: 125-130, 2002.
35. Pitha, P. M. Introduction: interferon's connection to cancer. Semin. Cancer Biol., 10: 69-72, 2000.